tiprankstipranks
OraSure price target raised by $2 at Citi, here’s why
The Fly

OraSure price target raised by $2 at Citi, here’s why

Citi analyst Patrick Donnelly raised the firm’s price target on OraSure to $9 from $7 and keeps a Buy rating on the shares. Heading into 2024, the analyst sees investor appetite across the life science tools space as “remaining light” following a challenging year with consistent downwards earnings revisions. The industry has seen a reset that will continue into next year driven by headwinds across biopharma with notable weakness in bioprocessing, instrumentation, and lingering challenges in China, the analyst tells investors in a research note. Going into next year, Citi sees modest downside to 2024 estimates in tools broadly, and names Bruker (BRKR) its top pick in tools, Qiagen (QGEN) our top pick in diagnostics, and Fortrea Holding (FTRE) its top pick in labs.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on OSUR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles